Prostaglandin E2 administered by subcutaneous pellets causes local inflammation and systemic bone loss: A model for inflammation-induced bone disease
Authors:
- 1 May 1993
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 8 (5) , 625-634
Abstract
The effects of prostaglandin E2 (PGE2) given in controlled-release pellets or by daily sc injection for 21 days on mineral homeostasis and bone histomorphometry were compared in 7-week-old female rats. Sham operation and ovariectomy were performed at the beginning of the studies. In experiment 1, 7.5 mg PGE2 or drug-free, controlled-release pellets were implanted sc at the back of the neck on day 7. In experiment 2, 3 mg/kg body weight of PGE2 or vehicle was injected sc daily beginning on day 7. The animals were sacrificed on day 28 of the two experiments, and the tibiae were removed for histomorphometric analysis of the diaphysis and metaphysis. When administered by pellets in experiment 1, PGE2 lowered serum 1,25-dihydroxyvitamin D and did not influence weight gain, serum calcium, phosphorus, or magnesium, cross-sectional or medullary areas, periosteal bone formation and apposition rates, endosteal bone formation and apposition rates, or endosteal tetracycline-labeled perimeter. PGE2 lowered cancellous bone area and cancellous bone perimeter in both the sham-operated and ovariectomized rats. In contrast, when administered by sc injection in experiment 2, PGE2 reduced weight gain, increased serum magnesium, increased cortical area, and reduced medullary area without changing cross-sectional area, increased periosteal bone formation and apposition rates and endosteal bone and apposition rates, did not alter endosteal tetracycline-labeled perimeter, and increased cancellous bone area and cancellous bone perimeter in both sham-operated and ovariectomized animals. PGE2 produced local inflammation when given by pellets, and the serum concentration of 13,14-dihydro-15-ketoprostaglandin E2, the major metabolite of PGE2, increased when PGE2 was given by sc injection but not when administered by pellets. Thus, PGE2 given sc by controlled-release pellets (1) produces local inflammation and systemic bone loss without increasing PGE2 systemically and (2) provides a model for inflammation-induced loss of cancellous bone. The results also indicate that the pellet is not a valid means for the delivery of PGE2 to the general circulation.Keywords
Funding Information
- Department of Veterans Affairs (AR 35651)
- U.S. Public Health Service
- Upjohn Company
This publication has 31 references indexed in Scilit:
- Prostaglandin E2 enhances cortical bone mass and activates intracortical bone remodeling in intact and ovariectomized female ratsBone, 1990
- Cellular basis of inflammation-induced osteopenia in growing ratsJournal of Bone and Mineral Research, 1988
- Indomethacin inhibition of tenotomy-induced bone resorption in ratsJournal of Bone and Mineral Research, 1988
- The role of bone cells in increasing metaphyseal hard tissue in rapidly growing rats treated with prostaglandin E2Bone, 1987
- The effects of immobilization on bone histomorphometry in ratsJournal of Bone and Mineral Research, 1986
- Effects of Parathyroid Hormone and Cortisol on Prostaglandin Production by Neonatal rat Calvaria in VitroEndocrine Research, 1985
- Cyclooxygenase products of arachidonic acid metabolism by mouse bone in organ cultureBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1980
- Bone remodelling induced by physical stress is prostaglandin E2 mediatedBiochimica et Biophysica Acta (BBA) - General Subjects, 1980
- Indomethacin Inhibits Bone Resorption and Lysosomal Enzyme Release from Bone in Organ CultureScandinavian Journal of Rheumatology, 1980
- Formation, mineralization, and resorption of bone in vitamin D—deficient ratsJournal of Clinical Investigation, 1970